← Back to Clinical Trials
Recruiting NCT07472985

NCT07472985 Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07472985
Status Recruiting
Phase
Sponsor Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Condition Spinal Cord Injuries
Study Type INTERVENTIONAL
Enrollment 102 participants
Start Date 2026-03-09
Primary Completion 2031-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
activity-based therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 102 participants in total. It began in 2026-03-09 with a primary completion date of 2031-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Spinal cord injuries (SCI) are among the most catastrophic survivable events experienced by human beings. Affected individuals remain with lifelong neurological impairment involving motor, sensory, bladder and bowel functions, which in turn impacts quality of life and independence. Currently, patients have no access to exercise therapy for weeks to months after the injury because clinicians remain fearful that early initiation of exercise therapy may be harmful to patients, and could lead to neurological deterioration. Patients are therefore mostly immobilized during the first weeks after the injury, and are at high risk of complications associated with immobility. In addition, there are compelling preclinical evidence showing that early exercise therapy is effective for promoting neurofunctional recovery. The PROMPT-SCI trial was the first to initiate early exercise therapy in the form of in-bed leg cycling within days after SCI. This trial has shown that it is safe and does not lead to neurological deterioration. However, in-bed leg cycling remains difficult to translate into the clinical environment of acute SCI, and its potential to decrease complications and improve neurofunctional recovery seems limited by the positioning in bed. The PROMPT-SCI II trial will therefore evaluate the potential of sitting leg cycling initiated within the first week of a SCI to decrease complications and improve neurofunctional recovery up to one year after the injury, in comparison to our prior data obtained with early in-bed cycling.

Eligibility Criteria

Inclusion Criteria: * adults 18 years or older with non-penetrating traumatic SCI * SCI severity AIS grade A (complete injury with no motor or sensory function below lesion), B (sensory but no motor function preserved) or C (motor function preserved with most key muscles unable to move against gravity) * NLI between C0 and L2; and spine surgery performed within 48 hours of SCI Exclusion Criteria: * intubated and mechanically ventilated * conditions interfering with patient safety or ability to undergo cycling * body mass index 40 kg/m2 or less (to prevent "frog leg" position during cycling) * moderate or severe traumatic brain injury * hemodynamic instability * pelvic or lower extremity * injury with weight-bearing or mobilization restrictions

Contact & Investigator

Central Contact

Jean-Marc Mac-Thiong, MD, PhD

✉ jean-marc.mac-thiong@umontreal.ca

📞 514-338-2222

Principal Investigator

Jean-Marc Mac-Thiong, MD, PhD

PRINCIPAL INVESTIGATOR

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Frequently Asked Questions

Who can join the NCT07472985 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07472985 currently recruiting?

Yes, NCT07472985 is actively recruiting participants. Contact the research team at jean-marc.mac-thiong@umontreal.ca for enrollment information.

Where is the NCT07472985 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT07472985 clinical trial?

NCT07472985 is sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. The principal investigator is Jean-Marc Mac-Thiong, MD, PhD at Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. The trial plans to enroll 102 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology